Literature DB >> 2347050

Timed sequential chemotherapy following ifosfamide-induced kinetic recruitment in refractory ovarian cancer.

R Rosso1, A Alama, L Repetto, P F Conte.   

Abstract

A total of 22 relapsed or refractory ovarian cancer patients were treated with ifosfamide-containing polychemotherapy. Kinetic analyses were done to evaluate the tumor-cell-recruiting potential of the alkylating agent. Our study shows that ifosfamide can enhance tumor proliferative activity in pretreated ovarian cancers.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2347050     DOI： 10.1007/bf00685417

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  25 in total

1.  Letter: Alkylating agents and myeloma cells.

Authors:  A Pileri; P F Conte; N Hulin
Journal:  Blood       Date:  1976-06       Impact factor: 22.113

2.  Correlation of cytosine arabinoside-induced increment in growth fraction of leukemic blast cells with clinical response.

Authors:  W R Vogler; L E Cooper; D P Groth
Journal:  Cancer       Date:  1974-03       Impact factor: 6.860

Review 3.  Kinetics of normal and leukemic leukocyte populations and relevance to chemotherapy.

Authors:  H E Skipper; S Perry
Journal:  Cancer Res       Date:  1970-06       Impact factor: 12.701

4.  Intensive timed sequential combination chemotherapy in extensive-stage small cell carcinoma of the lung.

Authors:  M Markman; K B Pendergrass; M D Abeloff
Journal:  Cancer Treat Rep       Date:  1982-10

5.  A rationale for sequential high-dose chemotherapy of leukemia timed to coincide with induced tumor proliferation.

Authors:  P J Burke; W P Vaughan; J E Karp
Journal:  Blood       Date:  1980-06       Impact factor: 22.113

6.  Pretherapeutic detection of tumour resistance and the results of tumour chemotherapy.

Authors:  M Volm; K Wayss; M Kaufmann; J Mattern
Journal:  Eur J Cancer       Date:  1979-07       Impact factor: 9.162

7.  Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results.

Authors:  W Scheef; H O Klein; N Brock; H Burkert; U Günther; H Hoefer-Janker; D Mitrenga; J Schnitker; R Voigtmann
Journal:  Cancer Treat Rep       Date:  1979-03

8.  Expansion of the growth fraction in multiple myeloma with alkylating agents.

Authors:  S E Salmon
Journal:  Blood       Date:  1975-01       Impact factor: 22.113

9.  A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.

Authors:  P F Conte; M Bruzzone; S Chiara; M R Sertoli; M G Daga; A Rubagotti; A Conio; M Ruvolo; R Rosso; L Santi
Journal:  J Clin Oncol       Date:  1986-06       Impact factor: 44.544

10.  Cytokinetically based induction chemotherapy and splenectomy for childhood acute nonlymphocytic leukemia.

Authors:  G V Dahl; D K Kalwinsky; S Murphy; A T Look; S Amadori; M Kumar; R Novak; S L George; C Mason; A M Mauer; J V Simone
Journal:  Blood       Date:  1982-10       Impact factor: 22.113
View more
  1 in total

Review 1.  Kinetic resistance to anticancer agents.

Authors:  M T Dimanche-Boitrel; C Garrido; B Chauffert
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.